Memogalin

Aripiprazole, the active ingredient in Memogalin, is an atypical antipsychotic presented as an oral tablet for oral use. It treats schizophrenia, bipolar I disorder, major depressive disorder (as adjunctive therapy) and irritability associated with autistic disorder in adults.

GNH USA supplies Memogalin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Aripiprazole is an atypical antipsychotic that modulates dopamine and serotonin pathways in several psychiatric conditions.

Schizophrenia: reduces psychotic symptoms and lowers relapse risk. Bipolar I disorder: stabilises mood and diminishes manic episodes. Major depressive disorder (adjunctive therapy): enhances response when added to standard antidepressants. Irritability associated with autistic disorder: decreases aggression and mood swings.

Common Side Effects: - Akathisia (inner restlessness) - Nausea or vomiting - Insomnia or sleep disturbances - Headache - Weight gain or increased appetite - Restlessness or agitation

Serious or Rare Side Effects: - Neuroleptic malignant syndrome (life‑threatening reaction) - Tardive dyskinesia (involuntary movements) - Suicidal thoughts or behaviours - Severe hypotension or cardiovascular collapse - Seizures or convulsions

Before initiating therapy, consider the following precautions: - Hepatic impairment: adjust dose based on liver function. - Suicidal ideation: monitor patients with depression closely. - Cardiovascular disease: assess risk of orthostatic hypotension. - Discontinuation: avoid abrupt cessation to prevent withdrawal symptoms. - Metabolic changes: monitor weight, glucose and lipid levels regularly. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Aripiprazole may interact with several medicines; review patient medication lists carefully.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) – increase aripiprazole plasma levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) – reduce aripiprazole exposure. - Monoamine oxidase inhibitors – risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - SSRIs (e.g., fluoxetine, sertraline) – may heighten akathisia. - Antihypertensives – additive blood‑pressure‑lowering effect. - Alcohol – can enhance central nervous system depression. - Anticholinergic agents – may mask certain side‑effects.